Mayo Medical Laboratories is now offering serum thyroglobulin (Tg) testing using SISCAPA technology and liquid chromatography, tandem mass spectrometry (SISCAPA-MS). Serum Tg measurements are central to monitoring treated thyroid cancer patients for persistent or recurrent disease. For decades, Tg measurements have relied on methods that are subject to interference by anti-Tg autoantibodies, which might be found in 20% to 30% of thyroid cancer patients. As a result, say SISCAPA Assay Technologies (SAT) representatives, many patients are being subjected to additional imaging studies that might be avoided by utilizing a more specific laboratory testing method.
“By adding this test, we are now able to provide more meaningful test results in cases of thyroglobulin autoantibody interference where the physicians were unsure about the disease status of the patient,” says Stefan K. Grebe, MD, PhD, Chair of Clinical Biochemistry and Immunology at Mayo Clinic.
SISCAPA-MS measures unique peptides to avoid autoantibody interferences, and incorporates internal standards to correct for many sample processing and assay problems. It was developed to provide a flexible multiplex assay-development platform for creation of assays to verify clinical utility of candidate protein biomarkers in large sample sets. As a licensee of SISCAPA technology, Mayo has developed a robust and sensitive laboratory test for the thyroid cancer tumor marker Tg.
“We are proud to have Mayo as a licensee,” says Selena Larkin, Vice President of Marketing and Sales for SAT, “and we congratulate them on the development of this new test for cancer recurrence.” Learn more about services, products, applications, and technologies provided by SISCAPA Assay Technologies.
Read more
